Cara Q3 net loss $23.2M; KORSUVA revenue $16.2M, 180K vials shipped

Tvardi Therapeutics, Inc.

2022-Q3 EPS reported -$1.03 revenue$38,606,000

Net loss $23.2M ($0.43/share) vs $1.0M loss ($0.02) in Q3 2021; total revenue $10.8M down from $20.3M.
KORSUVA injection net sales $16.2M incl. $7.4M profit-share from Vifor; ~180K vials shipped to dialysis centers.
Discontinued Phase 2 PBC trial due to slow enrollment; FDA meeting in 4Q22 to discuss NP pivotal program.
Cash $179.5M at Sept 30, 2022 (Dec 2021: $236.8M); expects to fund ops into first half 2024.
Appointed Ryan Maynard as CFO and Lisa von Moltke to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tvardi Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $16.2M.

Period: the third quarter ended September 30, 2022
Revenue: $16.2M
Result: reported results

Exact text from the filing

Cara Therapeutics Reports Third Quarter 2022 Financial Results – Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-115418

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.